Trending Now
Corcept Therapeutics (NASDAQ:CORT) Commences Enrolment In GRATITUDE II Trial For Miricorilant...
Corcept Therapeutics Incorporated (NASDAQ:CORT) has enrolled the first subject in its GRATITUDE II Phase 2 double-blind, randomized, placebo-controlled study of miricorilant in obese patients...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Nuwellis, Inc. (NUWE) Stock Surges Over 106% After Major CMS Reimbursement...
On November 4, 2024, Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on advanced solutions for fluid overload management, experienced a...
MAKE IT MODERN
LATEST REVIEWS
Ocugen Inc (NASDAQ: OCGN) Announces the Recommendation By The Independent Data...
Ocugen Inc (NASDAQ: OCGN) recently announced that the Independent Data and safety monitory Board evaluated the safety data recorded during the clinical trial of...
MAKE IT MODERN
PERFORMANCE TRAINING
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN:BTX) Clinches An Exclusive License mRNA Gene Editing Technology From Novellus...
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN:BTX) exercised its previously announced option and clinched an exclusive license for the mRNA gene editing/ cell therapies technology.
As per the...
MacroGenics Inc. (NASDAQ:MGNX) Announce Publication Of Research Supporting flotetuzumab Study in AML Patients In...
MacroGenics Inc. (NASDAQ:MGNX) has announced the publication of research in the journal of Science Translational medicine that supports the company's pivotal flotetuzumab study in...
Wall Street eyes TLT (NASDAQ:TLT) short
I hope everyone had a restful Thanksgiving and that you’re ready to ride the bulls ?
TLT (NASDAQ:TLT) is...
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) Announces Its Q3 2020 Financial Results And Provided Clinical Development...
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) has announced its Q3 2020 financial results and provided business highlights. The company recognized revenue of $48.9 million in Q3...
Fate Therapeutics Inc. (NASDAQ:FATE) Reports Revenue Of $7.6 Million in Q3 2020 And Progress...
Fate Therapeutics Inc. (NASDAQ:FATE) has announced its Q3 financial results and provided business highlights for the three months ended September 30, 2020. Revenue in...
MAKE IT MODERN
